|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,546,367: Scope, Claims, and Landscape
U.S. Patent 8,546,367, titled "INHALATION THERAPY DEVICE AND METHOD," describes an improved inhaler system designed for delivering therapeutic agents. The patent focuses on a device that enhances aerosol generation efficiency, dose uniformity, and patient compliance through specific design elements and operational mechanisms. The claims delineate a system comprising a mouthpiece, a valve, a nebulizer cup, and a power source, with particular emphasis on a vibrating mesh or perforated plate that oscillates to produce an aerosol.
What is the Core Technology Protected by U.S. Patent 8,546,367?
The patent protects a nebulizer system that utilizes a vibrating element to aerosolize liquid medicaments. The key innovation lies in the specific design and function of the vibrating mesh or perforated plate, which is driven by a power source to create fine droplets for inhalation. This method aims to improve the efficiency of drug delivery to the lungs compared to older nebulizer technologies.
The device is designed to be portable and user-friendly, facilitating easier administration of respiratory medications. The claims detail the interrelationship of the components and their roles in generating and delivering a consistent and respirable aerosol.
What are the Key Claims of U.S. Patent 8,546,367?
U.S. Patent 8,546,367 contains multiple independent and dependent claims that define the scope of the protected technology. The primary claims focus on the structure and operation of the nebulizer device.
Key Claim Elements:
-
Claim 1 (Independent): This claim defines an inhalation therapy device that includes:
- A housing containing a power source and an oscillator.
- A nebulizer cup configured to receive a liquid therapeutic agent.
- A mesh member disposed within the nebulizer cup, comprising a plurality of apertures.
- The oscillator is coupled to the mesh member and is operable to vibrate the mesh member, causing the liquid therapeutic agent to be aerosolized through the apertures.
- A mouthpiece in fluid communication with the nebulizer cup to direct the aerosol to a user.
- A valve system that is operatively connected to the mouthpiece and configured to allow the aerosol to pass to the user during inhalation and to prevent backflow of exhaled air.
-
Dependent Claims: These claims further refine the independent claims by adding specific features or limitations, such as:
- The size and configuration of the apertures in the mesh member.
- The material composition of the mesh member.
- The specific mechanism of vibration (e.g., piezoelectric).
- The design of the valve system to ensure efficient delivery and prevent waste.
- The power source and its integration with the housing for portability.
- The nebulizer cup's capacity and shape.
The patent's claims are designed to cover a range of nebulizer devices that employ a vibrating mesh technology for aerosol generation, with specific emphasis on the efficiency and control of the aerosolization process and the resulting therapeutic delivery.
How Does the Technology in Patent 8,546,367 Compare to Existing Nebulizer Technologies?
The technology described in U.S. Patent 8,546,367 represents an advancement over traditional jet nebulizers and metered-dose inhalers (MDIs).
Comparison Points:
- Jet Nebulizers: These devices use compressed air to break down liquid medication into fine droplets. They can be noisy, bulky, and require a power source for the air compressor. The delivery time can also be lengthy.
- Metered-Dose Inhalers (MDIs): These use a propellant to deliver a measured dose of medication in a short burst. While portable, they require specific inhalation technique and can sometimes lead to oral deposition of medication.
- Vibrating Mesh Nebulizers (VMNs) as described in Patent 8,546,367:
- Efficiency: VMNs generally produce smaller and more uniform droplet sizes, leading to more efficient deposition in the lower respiratory tract.
- Portability: The vibrating mesh technology allows for smaller, lighter, and quieter devices, often battery-powered, enhancing portability.
- Speed: VMNs can deliver medication faster than traditional jet nebulizers.
- Dose Uniformity: The controlled vibration mechanism can lead to more consistent dosing with each actuation.
- Noise: VMNs are significantly quieter than jet nebulizers.
Patent 8,546,367 specifically addresses improvements in these areas, aiming to optimize aerosol particle size distribution, minimize residual medication in the nebulizer cup, and improve the overall patient experience.
What is the Patent Landscape for Vibrating Mesh Nebulizer Technology?
The patent landscape for vibrating mesh nebulizer (VMN) technology is dynamic and competitive, with numerous patents filed by major pharmaceutical and medical device companies. U.S. Patent 8,546,367 is one component within this broader landscape.
Key Players and Trends:
- Major Filers: Companies such as OMRON Healthcare, Philips Respironics, PARI Respiratory, and Teva Pharmaceutical Industries are significant patent holders in the nebulizer space.
- Technological Focus: Patents in this area often cover:
- Innovations in mesh design (aperture size, density, material).
- Improvements in actuator mechanisms (e.g., piezoelectric transducers).
- Device miniaturization and battery technology for enhanced portability.
- Smart features for dose tracking and adherence monitoring.
- Antimicrobial properties of materials.
- Specific drug formulations optimized for VMN delivery.
- Patent Protection Strategy: Companies file broad claims to cover variations of the core technology, as well as narrower claims for specific design enhancements. This creates a complex web of overlapping and complementary intellectual property.
- Freedom to Operate (FTO) Considerations: Companies seeking to develop or market VMN devices must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including those related to U.S. Patent 8,546,367.
The existence of U.S. Patent 8,546,367 indicates a recognized innovation in VMN technology, and its scope would need to be assessed in conjunction with other patents covering similar or overlapping aspects of mesh nebulizer systems.
What is the Exclusivity Period for U.S. Patent 8,546,367?
U.S. Patent 8,546,367 was filed on November 2, 2011, and issued on October 8, 2013. Under U.S. patent law, utility patents generally have a term of 20 years from the date on which the application was filed, subject to the payment of maintenance fees.
Exclusivity Timeline:
- Filing Date: November 2, 2011
- Issue Date: October 8, 2013
- Expiration Date: November 2, 2031 (20 years from filing date)
During this period, the patent holder has the exclusive right to make, use, sell, and import the invention claimed in the patent within the United States. After the patent expires, the technology enters the public domain, and others are free to use it without permission.
What are the Potential Implications of U.S. Patent 8,546,367 for New Market Entrants?
For new market entrants in the nebulizer space, U.S. Patent 8,546,367 presents both challenges and potential opportunities, depending on their intended technology.
Key Considerations:
- Infringement Risk: Any device that incorporates the specific combination of elements and operational principles described in the independent claims of U.S. Patent 8,546,367 without proper licensing or authorization risks patent infringement. This includes devices that utilize a vibrating mesh or perforated plate to aerosolize liquid medicaments in a manner substantially similar to that claimed.
- Freedom to Operate (FTO) Analysis: A comprehensive FTO analysis is critical. This involves mapping the claims of Patent 8,546,367 against the proposed product's design and functionality. If the proposed product falls within the scope of any of the patent's claims, infringement is likely.
- Licensing Opportunities: If a new entrant's technology closely aligns with the patented invention, they may need to seek a license from the patent holder to commercialize their product. This would involve negotiating terms and royalty payments.
- Design-Around Strategies: Entrants can attempt to design around the patent by developing alternative technologies or modifications that do not fall within the scope of the patent's claims. This requires a deep understanding of the patent's language and scope. For example, developing a VMN that operates on a fundamentally different vibration mechanism or has a significantly different arrangement of components might avoid infringement.
- Post-Expiration Opportunities: Once the patent expires in November 2031, the core technology will be available for general use, potentially opening avenues for market entry based on this specific innovation.
- Patent Validity: Entrants may also investigate the possibility of challenging the validity of the patent based on prior art or other legal grounds, though this is a complex and costly endeavor.
The existence and claims of U.S. Patent 8,546,367 necessitate careful due diligence to navigate the intellectual property landscape effectively.
Key Takeaways
U.S. Patent 8,546,367 protects a specific vibrating mesh nebulizer technology designed for efficient and portable drug delivery. The patent's claims detail a system comprising a housing, power source, oscillator, nebulizer cup, vibrating mesh, mouthpiece, and valve. The technology offers advantages over older nebulizer types in terms of efficiency, portability, speed, and noise. The patent is in force until November 2, 2031, requiring new market entrants to conduct thorough freedom-to-operate analyses and consider licensing or design-around strategies to avoid infringement.
FAQs
-
What is the primary function of the vibrating mesh in U.S. Patent 8,546,367?
The primary function is to aerosolize a liquid therapeutic agent by vibrating at a frequency that causes the liquid to pass through a plurality of apertures, forming fine droplets for inhalation.
-
Can I use the technology described in U.S. Patent 8,546,367 after its expiration date?
Yes, once U.S. Patent 8,546,367 expires on November 2, 2031, the technology it protects will enter the public domain, and it can be used by anyone without requiring a license.
-
Does U.S. Patent 8,546,367 cover all vibrating mesh nebulizers?
No, the patent covers a specific configuration and operational method of a vibrating mesh nebulizer as defined by its claims. Other vibrating mesh nebulizers may operate differently or incorporate distinct features that fall outside the scope of this particular patent.
-
What types of therapeutic agents can be delivered using the device described in U.S. Patent 8,546,367?
The patent describes the device for delivering "liquid therapeutic agents," which generally includes medications for respiratory conditions such as asthma, COPD, and cystic fibrosis. Specific drug compatibility would depend on the formulation and the nebulizer's performance characteristics.
-
How does the valve system described in the patent contribute to the device's functionality?
The valve system is designed to allow the aerosolized medication to pass to the user only during inhalation, preventing wasted medication. It also prevents the backflow of exhaled air into the nebulizer cup, maintaining the integrity of the medication and the device.
Citations
[1] U.S. Patent No. 8,546,367 (filed Nov. 2, 2011; issued Oct. 8, 2013).
More… ↓
⤷ Start Trial
|
